Recent innovations in CAR construct design, such as incorporation of DAP12, 2B4, or FcRγ signaling domains, as well as synthetic control circuits and tumor microenvironment (TME)-responsive elements, have significantly improved the efficacy and safety of these potential therapies. The gene discussed is FCER1G; the disease is neoplasm.